RNTX (Rein Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


RNTX Rein Therapeutics Inc RNTX
30 GF Score
Price $1.01
! 1 Warning Sign
View Full Analysis

What is Rein Therapeutics FCF Margin %?

Rein Therapeutics RNTX +3.12% 30 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates RNTX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Rein Therapeutics ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Rein Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-3.42 Mil. Rein Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Rein Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Rein Therapeutics's current FCF Yield % is -19.23%.

The historical rank and industry rank for Rein Therapeutics's FCF Margin % or its related term are showing as below:


RNTX's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Rein Therapeutics FCF Margin % Related Terms

Rein Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Rein Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rein Therapeutics FCF Margin % Chart

Rein Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rein Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RNTX vs ATRA, OSTX, IBIO: FCF Margin % Comparison

For the Biotechnology subindustry, Rein Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rein Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rein Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Rein Therapeutics's FCF Margin % falls into.


RNTX
30GF Score
Rein Therapeutics Inc RNTX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rein Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Rein Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-19.361/0
= %

Rein Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-3.424/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Rein Therapeutics (RNTX) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rein Therapeutics and its competitors. According to the industry distribution chart, Rein Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is Rein Therapeutics' FCF Margin % too high?
Rein Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Rein Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rein Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rein Therapeutics' FCF Margin % compare to ATRA and OSTX?
According to the Biotechnology industry distribution chart, Rein Therapeutics ranks #999999 out of 959 companies for FCF Margin %. This places Rein Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rein Therapeutics and its competitors. Rein Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rein Therapeutics stock overvalued right now?
Rein Therapeutics (RNTX) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Rein Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Rein Therapeutics (RNTX), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rein Therapeutics Business Description

Address 12407 North Mopac Expressway, Suite 250, No.390, Austin, TX, USA, 78758
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
30GF Score

Get the complete analysis for RNTX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price